Novo Nordisk Implements Dual Strategy to Counter Market Pressure

Novo Nordisk launches a Wegovy subscription to compete with Eli Lilly and cuts 400 US manufacturing jobs, despite strong 2025 results and a cautious 2026 outlook.

Danish pharmaceutical giant Novo Nordisk is enacting a two-pronged approach in a competitive market, launching a subscription model for its weight-loss drug Wegovy while simultaneously cutting approximately 400 jobs at a key U.S. manufacturing site. These moves are a direct strategic response to intensifying rivalry from competitor Eli Lilly.

Cost-Cutting Amidst Strong Prior Performance

The backdrop for these operational shifts is the company's recent financial disclosure. On April 1, 2026, Novo Nordisk reported revenue of $43.27 billion and an operating profit of $17.88 billion, with both metrics showing growth exceeding ten percent in constant currencies. Despite this robust 2025 performance, management has issued a cautious outlook, projecting a decline in both revenue and operating profit of between five and thirteen percent for 2026.

This tempered forecast appears to be reflected in the company's share price, which has declined roughly 28 percent since the start of the year, trading significantly below its 200-day moving average.

Subscription Plan Aims to Lock In Patients

In a bid to secure price-sensitive customers, Novo Nordisk will introduce a subscription program for Wegovy (semaglutide) in the United States starting March 31, 2026. Patients paying out-of-pocket will have the option to choose three-, six-, or twelve-month membership plans. The most economical option, an annual subscription for the injectable medication, is priced at $249 per month, offering potential annual savings of up to $1,200 compared to the standard list price.

The pricing is strategically calculated. Eli Lilly currently offers its competing GLP-1 medication for approximately $300 monthly; Novo Nordisk's model deliberately undercuts this by about $50. Eli Lilly is estimated to hold around 60 percent of the U.S. prescription GLP-1 market, with Novo Nordisk commanding roughly 39 percent.

The subscription service will be accessible through digital health platforms including Ro, WeightWatchers, and LifeMD, with additional partners expected. This initiative is particularly significant for the growing segment of patients purchasing Wegovy without insurance coverage, as commercial health insurers increasingly restrict reimbursement for GLP-1 medications.

Workforce Reduction at Newly Acquired Facility

Concurrently, Novo Nordisk confirmed it is eliminating about 400 positions at its manufacturing plant in Bloomington, Indiana. This facility was acquired from Catalent in late 2024 for $16.5 billion. Following the cuts, which become effective in early May, the site will retain a workforce of approximately 1,400 employees.

This downsizing is notable given recent positive signals from the plant, where customers reported constructive discussions with the U.S. Food and Drug Administration (FDA) and a resumption of normal operations. The reduction indicates Novo Nordisk is realigning the site's cost structure, following a broader corporate initiative in 2025 that eliminated around 9,000 jobs globally.

A Unified Strategic Front

The subscription model and job cuts represent interconnected components of a single strategy: defending market share and reducing costs ahead of a pivotal competitive launch. Eli Lilly is expected to introduce a rival oral GLP-1 medication later in the year, heightening the urgency for Novo Nordisk to solidify its position and streamline operations.